{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:07:54Z","timestamp":1768194474323,"version":"3.49.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,12,6]],"date-time":"2012-12-06T00:00:00Z","timestamp":1354752000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s10549-012-2366-0","type":"journal-article","created":{"date-parts":[[2012,12,5]],"date-time":"2012-12-05T15:31:45Z","timestamp":1354721505000},"page":"449-455","source":"Crossref","is-referenced-by-count":40,"title":["Effect of HER2 status on distant recurrence in early stage breast cancer"],"prefix":"10.1007","volume":"137","author":[{"given":"Kenneth R.","family":"Hess","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco J.","family":"Esteva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,6]]},"reference":[{"key":"2366_CR1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1023\/A:1022166517963","volume":"78","author":"KR Hess","year":"2003","unstructured":"Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN (2003) Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 78:105\u2013118","journal-title":"Breast Cancer Res Treat"},{"key":"2366_CR2","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/annonc\/mdn036","volume":"19","author":"S Dawood","year":"2008","unstructured":"Dawood S, Broglio K, Esteva FJ et al (2008) Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 19:1242\u20131248","journal-title":"Ann Oncol"},{"key":"2366_CR3","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/annonc\/mdn427","volume":"19","author":"F Peintinger","year":"2008","unstructured":"Peintinger F, Buzdar AU, Kuerer HM et al (2008) Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol 19:2020\u20132025","journal-title":"Ann Oncol"},{"key":"2366_CR4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF03032345","volume":"7","author":"FJ Esteva","year":"2001","unstructured":"Esteva FJ, Hortobagyi GN, Sahin AA et al (2001) Expression of erbB\/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res 7:171\u2013177","journal-title":"Pathol Oncol Res"},{"key":"2366_CR5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/bcr777","volume":"6","author":"FJ Esteva","year":"2004","unstructured":"Esteva FJ, Hortobagi GN (2004) Prognostic molecular markers in early breast cancer. Breast Cancer Res 6:109\u2013118","journal-title":"Breast Cancer Res"},{"key":"2366_CR6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1053\/srao.2002.35251","volume":"12","author":"FJ Esteva","year":"2002","unstructured":"Esteva FJ, Sahin AA, Cristofanilli M et al (2002) Molecular prognostic factors for breast cancer metastasis and survival. Semin Radiat Oncol 12:319\u2013328","journal-title":"Semin Radiat Oncol"},{"key":"2366_CR7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.9-suppl_3-4","volume":"9","author":"FJ Esteva","year":"2004","unstructured":"Esteva FJ (2004) Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer. Oncologist 9:4\u20139","journal-title":"Oncologist"},{"key":"2366_CR8","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2353\/ajpath.2010.090885","volume":"177","author":"FJ Esteva","year":"2010","unstructured":"Esteva FJ, Guo H, Zhang S et al (2010) PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177:1647\u20131656","journal-title":"Am J Pathol"},{"key":"2366_CR9","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/cncr.22418","volume":"109","author":"C Mazouni","year":"2007","unstructured":"Mazouni C, Hall A, Broglio K et al (2007) Kinetics of serum HER-2\/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer 109:496\u2013501","journal-title":"Cancer"},{"key":"2366_CR10","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659\u20131672","journal-title":"N Engl J Med"},{"key":"2366_CR11","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673\u20131684","journal-title":"N Engl J Med"},{"key":"2366_CR12","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273\u20131283","journal-title":"N Engl J Med"},{"key":"2366_CR13","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1200\/JCO.2006.08.8575","volume":"24","author":"JL Khatcheressian","year":"2006","unstructured":"Khatcheressian JL, Wolff AC, Smith TJ et al (2006) American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 24:5091\u20135097","journal-title":"J Clin Oncol"},{"key":"2366_CR14","doi-asserted-by":"crossref","DOI":"10.1002\/9780470870709","volume-title":"Competing risks: a practical perspective","author":"M Pintilie","year":"2006","unstructured":"Pintilie M (2006) Competing risks: a practical perspective. Wiley, Hoboken"},{"key":"2366_CR15","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"3","author":"RJ Gray","year":"1988","unstructured":"Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 3:1141\u20131154","journal-title":"Ann Stat"},{"key":"2366_CR16","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496\u2013509","journal-title":"J Am Stat Assoc"},{"key":"2366_CR17","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00280-009-1190-7","volume":"66","author":"YH Park","year":"2010","unstructured":"Park YH, Lee S, Cho EY et al (2010) Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status. Cancer Chemother Pharmacol 66:507\u2013516","journal-title":"Cancer Chemother Pharmacol"},{"key":"2366_CR18","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","volume":"28","author":"H Kennecke","year":"2010","unstructured":"Kennecke H, Yerushalmi R, Woods R et al (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271\u20133277","journal-title":"J Clin Oncol"},{"key":"2366_CR19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","volume":"369","author":"I Smith","year":"2007","unstructured":"Smith I, Procter M, Gelber RD et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29\u201336","journal-title":"Lancet"},{"key":"2366_CR20","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/bcr3324","volume":"14","author":"I Vaz-Luis","year":"2012","unstructured":"Vaz-Luis I, Ottesen RA, Hughes ME et al (2012) Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res 14:R129","journal-title":"Breast Cancer Res"},{"key":"2366_CR21","doi-asserted-by":"crossref","unstructured":"Arvold ND, Oh KS, Niemierko A et al. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Res Treat 2012","DOI":"10.1007\/s10549-012-2243-x"},{"key":"2366_CR22","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1158\/1078-0432.CCR-06-2478","volume":"13","author":"NU Lin","year":"2007","unstructured":"Lin NU, Winer EP (2007) Brain metastases: the HER2 paradigm. Clin Cancer Res 13:1648\u20131655","journal-title":"Clin Cancer Res"},{"key":"2366_CR23","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/bjc.2012.346","volume":"107","author":"YS Yap","year":"2012","unstructured":"Yap YS, Cornelio GH, Devi BC et al (2012) Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. Br J Cancer 107:1075\u20131082","journal-title":"Br J Cancer"},{"key":"2366_CR24","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/cncr.25771","volume":"117","author":"A Musolino","year":"2011","unstructured":"Musolino A, Ciccolallo L, Panebianco M et al (2011) Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer 117:1837\u20131846","journal-title":"Cancer"},{"key":"2366_CR25","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1093\/annonc\/mdq625","volume":"22","author":"F Heitz","year":"2011","unstructured":"Heitz F, Rochon J, Harter P et al (2011) Cerebral metastases in metastatic breast cancer: disease-specific risk factors and survival. Ann Oncol 22:1571\u20131581","journal-title":"Ann Oncol"},{"key":"2366_CR26","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ijrobp.2009.06.030","volume":"77","author":"A Niwinska","year":"2010","unstructured":"Niwinska A, Tacikowska M, Murawska M (2010) The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death. Int J Radiat Oncol Biol Phys 77:1134\u20131139","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2366_CR27","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10549-008-0275-z","volume":"117","author":"R Duchnowska","year":"2009","unstructured":"Duchnowska R, Dziadziuszko R, Czartoryska-Arlukowicz B et al (2009) Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Res Treat 117:297\u2013303","journal-title":"Breast Cancer Res Treat"},{"key":"2366_CR28","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2009.06.027","volume":"45","author":"F Heitz","year":"2009","unstructured":"Heitz F, Harter P, Lueck HJ et al (2009) Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 45:2792\u20132798","journal-title":"Eur J Cancer"},{"key":"2366_CR29","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/annonc\/mdl064","volume":"17","author":"BC Pestalozzi","year":"2006","unstructured":"Pestalozzi BC, Zahrieh D, Price KN et al (2006) Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 17:935\u2013944","journal-title":"Ann Oncol"},{"key":"2366_CR30","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1002\/cncr.11436","volume":"97","author":"JC Bendell","year":"2003","unstructured":"Bendell JC, Domchek SM, Burstein HJ et al (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972\u20132977","journal-title":"Cancer"},{"key":"2366_CR31","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1200\/JCO.2004.01.175","volume":"22","author":"NU Lin","year":"2004","unstructured":"Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22:3608\u20133617","journal-title":"J Clin Oncol"},{"key":"2366_CR32","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B","volume":"52","author":"Y Tsukada","year":"1983","unstructured":"Tsukada Y, Fouad A, Pickren JW, Lane WW (1983) Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 52:2349\u20132354","journal-title":"Cancer"},{"key":"2366_CR33","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/annonc\/mdn682","volume":"20","author":"S Dawood","year":"2009","unstructured":"Dawood S, Broglio K, Esteva FJ et al (2009) Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 20:621\u2013627","journal-title":"Ann Oncol"},{"key":"2366_CR34","doi-asserted-by":"crossref","first-page":"5278","DOI":"10.1200\/JCO.2008.19.8481","volume":"27","author":"B Leyland-Jones","year":"2009","unstructured":"Leyland-Jones B (2009) Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 27:5278\u20135286","journal-title":"J Clin Oncol"},{"key":"2366_CR35","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10549-007-9663-z","volume":"109","author":"E Bria","year":"2008","unstructured":"Bria E, Cuppone F, Fornier M et al (2008) Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 109:231\u2013239","journal-title":"Breast Cancer Res Treat"},{"key":"2366_CR36","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/cncr.20530","volume":"101","author":"AM Gonzalez-Angulo","year":"2004","unstructured":"Gonzalez-Angulo AM, Cristofanilli M, Strom EA et al (2004) Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer 101:1760\u20131766","journal-title":"Cancer"},{"key":"2366_CR37","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783\u2013792","journal-title":"N Engl J Med"},{"key":"2366_CR38","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1200\/JCO.2002.07.058","volume":"20","author":"FJ Esteva","year":"2002","unstructured":"Esteva FJ, Valero V, Booser D et al (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20:1800\u20131808","journal-title":"J Clin Oncol"},{"key":"2366_CR39","first-page":"38","volume":"27","author":"M Fornier","year":"2000","unstructured":"Fornier M, Esteva FJ, Seidman AD (2000) Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Semin Oncol 27:38\u201345","journal-title":"Semin Oncol"},{"key":"2366_CR40","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2010.32.2321","volume":"29","author":"PK Morrow","year":"2011","unstructured":"Morrow PK, Wulf GM, Ensor J et al (2011) Phase I\/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 29:3126\u20133132","journal-title":"J Clin Oncol"},{"key":"2366_CR41","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/bcr2324","volume":"11","author":"PK Morrow","year":"2009","unstructured":"Morrow PK, Zambrana F, Esteva FJ (2009) Recent advances in systemic therapy: advances in systemic therapy for HER2-positive metastatic breast cancer. Breast Cancer Res 11:207","journal-title":"Breast Cancer Res"},{"key":"2366_CR42","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0889-8588(05)70065-4","volume":"13","author":"FJ Esteva","year":"1999","unstructured":"Esteva FJ, Hortobagyi GN (1999) Locally advanced breast cancer. Hematol Oncol Clin North Am 13:457\u2013472","journal-title":"Hematol Oncol Clin North Am"},{"key":"2366_CR43","doi-asserted-by":"crossref","unstructured":"Dean-Colomb W, Esteva FJ. Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer. Semin Oncol 2008; 35: S31\u2013S38; quiz S40","DOI":"10.1053\/j.seminoncol.2008.02.008"},{"key":"2366_CR44","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1158\/1535-7163.MCT-06-0423","volume":"6","author":"R Nahta","year":"2007","unstructured":"Nahta R, Yuan LX, Du Y, Esteva FJ (2007) Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 6:667\u2013674","journal-title":"Mol Cancer Ther"},{"key":"2366_CR45","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nrclinonc.2009.216","volume":"7","author":"FJ Esteva","year":"2010","unstructured":"Esteva FJ, Yu D, Hung MC, Hortobagyi GN (2010) Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol 7:98\u2013107","journal-title":"Nat Rev Clin Oncol"},{"key":"2366_CR46","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733\u20132743","journal-title":"N Engl J Med"},{"issue":"7418","key":"2366_CR47","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"DC Koboldt","year":"2012","unstructured":"Koboldt DC, Fulton RS, McLellan MD et al (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61\u201370","journal-title":"Nature"},{"key":"2366_CR48","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.2011.36.2574","volume":"30","author":"T Iwamoto","year":"2012","unstructured":"Iwamoto T, Booser D, Valero V et al (2012) Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol 30:729\u2013734","journal-title":"J Clin Oncol"},{"key":"2366_CR49","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nature11017","volume":"486","author":"PJ Stephens","year":"2012","unstructured":"Stephens PJ, Tarpey PS, Davies H et al (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486:400\u2013404","journal-title":"Nature"},{"key":"2366_CR50","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S1470-2045(10)70018-8","volume":"11","author":"N Juul","year":"2010","unstructured":"Juul N, Szallasi Z, Eklund AC et al (2010) Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol 11:358\u2013365","journal-title":"Lancet Oncol"},{"key":"2366_CR51","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1158\/1078-0432.CCR-09-1735","volume":"15","author":"EA Mittendorf","year":"2009","unstructured":"Mittendorf EA, Wu Y, Scaltriti M et al (2009) Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 15:7381\u20137388","journal-title":"Clin Cancer Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2366-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-012-2366-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2366-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T13:11:34Z","timestamp":1562418694000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-012-2366-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,6]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["2366"],"URL":"https:\/\/doi.org\/10.1007\/s10549-012-2366-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,6]]}}}